Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

PauseRX vs TelePeptide

PauseRX
Graded #150

Higher grade

vs+6.200000000000003
TelePeptide
Graded #276

Lower grade

The verdict

PauseRX takes it — 68.5/100 to 62.3/100.

PauseRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PauseRX is a nationwide compounded GLP-1 telehealth platform notable for its transparency: it names its 503A pharmacy partner (Strive Pharmacy in Gilbert, AZ), its physician network (Beluga Health), and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePauseRX +22
66
44
Dose & formulationPauseRX +10
85
75
Clinical oversightTelePeptide +4
83
87
Labs & monitoringTelePeptide +2
52
54
FulfillmentTelePeptide +16
61
77
Contract termsPauseRX +21
41
20
PauseRX · left barTelePeptide · right bar

The numbers

MetricPauseRXTelePeptide
WeighScore68.5/10062.3/100
GradeCC
Scorecard rank#150#276
Semaglutide$199/mo$199/mo (starting dose, annual plan, compounded oral)
Tirzepatide$249/mo (starting dose, compounded)$219/mo (starting dose, annual plan, compounded oral)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
PauseRX

Graded #150 · C

Strengths

  • Names its 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) — buyers can independently verify its licensure
  • Names its physician network (Beluga Health) — you can research the clinical platform handling your prescriptions
  • Publishes the FDA compounded-medication disclaimer
  • Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for direct-to-consumer GLP-1 platforms
  • Flat $199 'all doses' compounded semaglutide pricing — no per-tier escalation

Where it loses points

  • States served not listed — site claims nationwide, but you must contact support to confirm availability
  • Restrictive cancellation policy — orders can't be changed or canceled once submitted, and medications can't be returned
  • No named medical director (Beluga Health is the network, not a named MD)
  • LegitScript certification number not shown — badge only, so no direct lookup
  • Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed
TelePeptide

Graded #276 · C

Strengths

  • LegitScript-certified (seal ID 49966407); 503A-licensed compounding pharmacies
  • All-inclusive from $169/mo annual — physician eval + Rx + medication + shipping, no hidden fees
  • Broadest formulation menu: injectable sema/tirz, oral dissolvable tablets, sema+naltrexone, microdose combos
  • 24/7 care team messaging + regular check-ins + dosage adjustments included at every tier
  • 48 states + DC coverage (excludes only AK + MS); no insurance required; cancel anytime

Where it loses points

  • Compounded medications are not FDA-approved; no pharmacy partner named publicly
  • Monthly billing costs more — $199/mo (monthly) vs $169/mo (annual) for semaglutide injectable; best rate requires annual prepay
  • Labs not included in any plan
  • Founder disclosed by first name only (Ahmed); no physician names or clinical leadership disclosed publicly
  • Tirzepatide injectable at $249/mo (monthly billing) is above the compounded market average

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard